Envista (NYSE:NVST) Given New $22.00 Price Target at JPMorgan Chase & Co.

Envista (NYSE:NVST) had its price target hoisted by JPMorgan Chase & Co. from $20.00 to $22.00 in a report published on Tuesday,Benzinga reports. The firm currently has a neutral rating on the stock.

Several other research firms have also recently issued reports on NVST. Zacks Research cut Envista from a “strong-buy” rating to a “hold” rating in a research note on Monday, September 15th. Robert W. Baird set a $27.00 price target on Envista in a research report on Friday, October 31st. Wall Street Zen raised shares of Envista from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 1st. Mizuho set a $19.00 price objective on shares of Envista in a research report on Monday, November 3rd. Finally, Weiss Ratings restated a “sell (d)” rating on shares of Envista in a research note on Monday, December 8th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $21.77.

Envista Price Performance

Shares of Envista stock opened at $21.91 on Tuesday. The company’s fifty day simple moving average is $20.22 and its two-hundred day simple moving average is $20.19. Envista has a 12-month low of $14.22 and a 12-month high of $22.68. The firm has a market cap of $3.60 billion, a PE ratio of 243.47, a price-to-earnings-growth ratio of 1.09 and a beta of 1.02. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its earnings results on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.05. The company had revenue of $669.90 million during the quarter, compared to analyst estimates of $639.49 million. Envista had a net margin of 0.58% and a return on equity of 5.90%. Envista’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.12 earnings per share. As a group, equities analysts expect that Envista will post 1 EPS for the current year.

Institutional Investors Weigh In On Envista

Several large investors have recently bought and sold shares of NVST. Alliancebernstein L.P. lifted its stake in shares of Envista by 1,985.1% during the 1st quarter. Alliancebernstein L.P. now owns 4,550,789 shares of the company’s stock worth $78,547,000 after acquiring an additional 4,332,541 shares during the last quarter. Holocene Advisors LP bought a new stake in shares of Envista during the second quarter worth $43,936,000. Norges Bank purchased a new stake in shares of Envista during the second quarter valued at $40,229,000. Dimensional Fund Advisors LP boosted its stake in shares of Envista by 24.0% during the first quarter. Dimensional Fund Advisors LP now owns 8,387,297 shares of the company’s stock valued at $144,760,000 after purchasing an additional 1,625,206 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of Envista by 16.7% in the second quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock worth $175,011,000 after purchasing an additional 1,284,767 shares during the last quarter.

Envista Company Profile

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.